GLG News by Medical Device Experts

A new, blood-based molecular diagnostic screening test for colorectal cancer could revolutionize screening for this disease.  Third party payors would rapidly embrace and reimburse for a cost-effective way to reduce conventional screening procedures and the mortality associated with this disease....

Roche's (SWX: ROG.VX; RO.S; OTCQX: RHHBY) acquisition of Ventana Medical Systems Inc. (Nasdaq: VMSI) is yet another example of the rapid consolidation in the clinical diagnostics market segment.  Roche Diagnostics is the worldwide leader in the clinical diagnostics space.  The Ventana acquisition...

The rapid growth of genetic testing has prompted calls from various agencies and organizations for improved regulations of these tests by the Centers for Medicare and Medicaid Services (CMS).  Increased regulation could impact the growth and profitability of these tests.  However,...

Sepsis is the leading cause of mortality in the United States, responsible for over 215,000 deaths per year.   While sepsis sometimes arises from an infection in an otherwise healthy person, all hospital patients are at risk. But identifying patients with sepsis is difficult because its...

MRSA continues to be top major problem plaguing global healthcare systems.  Several companies are working to provide innovative, cost-effective solutions to combat this drug resistant disease that costs the US healthcare system over $30 billion each year.  As more companies enter...

The market for MRSA screening continues to develop as companies launch new, improved techologies to meet laboratory needs.  The CDC estimates that 94,000 patients are infected with MRAS each year, resulting in approximately 19,000 deaths.  Recent media focus on MRSA infections, both in acute...

New developments in lung cancer may help diagnose a disease which is responsible for over 156,000 deaths per year in the United States.  Rosetta Genomics (ROSG) selected real time PCR from Roche Diagnostics (ROG.VX) and Nanogen's (NGEN) MGB probe technology for 3 new tests expected to be launched...

A new study published in the Journal of the American Medical Association estimated a lower risk of developing breast cancer by the age of 70 in women carrying mutations in one of two genes (BRAC1 and BRAC2).  This comes at the same time as Myriad Genetics (MYGN) is marketing their BRAC1/BRAC2...

Agendia announced the completion of a clinical study demonstrating the value of its Mamaprint(R) breast cancer prognosis test in postmenopausal women.  Agendia believes that this data will enable it to file for expanded claims with the FDA for Mamaprint(R).  Expanded claims for Agendia's DNA...

    Product shelf-life is a major economic concern for the agricultural industry.   The biological mechanism for regulating the ripening of fruits is mediated by ethylene.     Ethylene  management is addressed in three ways: 1) Ethylene...